Stuart L. Goldberg

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes et al. · The Lancet Oncology · 2017 · 488 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Robertson, Brad S. Kahl, Julie M. Vose et al. · Journal of Clinical Oncology · 2007 · 231 citations

Medicine, Oncology, Pharmacology +15

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

Susan O’Brien, Gary J. Schiller, John Lister et al. · Journal of Clinical Oncology · 2012 · 188 citations

Pharmacy, Oncology, Pharmacotherapy +17

COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey

Richard Tsai, John G. Hervey, Kathleen Hoffman et al. · JMIR Public Health and Surveillance · 2021 · 180 citations · Full text

Medicine, Community Health, Immunology +17

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

Stefan Faderl, Meir Wetzler, David A. Rizzieri et al. · Journal of Clinical Oncology · 2012 · 176 citations · Full text

Medicine, Oncology, Pharmacotherapy +13